COMMUNIQUÉS West-GlobeNewswire

University of West England Adopts HeartSciences’ MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center
05/02/2026
Southlake, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. ( Nasdaq: HSCS; HSCSW ) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing electrocardiography (“ECG” or [...]
Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
05/02/2026
– Live video webcast on Wednesday, February 11 th at 1:20 PM EST HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it will [...]
PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health
05/02/2026
Milestone reflects accelerating adoption of innovative, non-surgical treatment options for uterine conditions TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “ [...]
Microbot Medical® to Leverage Current Users Experience of the LIBERTY® Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption
05/02/2026
Participating at the Society of Interventional Oncology Conference Will Allow the Company to Share Practical Insights and Personal Experiences HINGHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. ( [...]
Catheter Precision’s LockeT Suture Retention Device to be Featured in Live Cases at Scripps’ Structural Heart Intervention and Imaging 2026 Conference
05/02/2026
FORT MILL, S.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a pioneer in medical technology for the cardiac electrophysiology market, today announced that its LockeT suture [...]
LB Pharmaceuticals Announces $100.0 Million Private Placement
05/02/2026
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar [...]
Basic Jane Advances Science-Led Cannabinoid Platform Focused on Senior Care and Scalable Product Formats
05/02/2026
SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Basic Jane, a consumer product–focused subsidiary of Verda Bio, today highlighted its evolution from a mission-driven CBD brand into a scalable, partner-ready cannabinoid [...]
FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia
05/02/2026
HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the [...]
EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB
05/02/2026
GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million. Reference is made to the stock exchange announcement published on 27 January 2026 by EXACT [...]
Aclarion Publishes 2026 Shareholder Letter from the Chairman
05/02/2026
Company anticipates no capital raises prior to expected value enhancing catalysts Cash runway into 2028 ATM terminated in early 2025 and ELOC expired December 31, 2025 BROOMFIELD, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE [...]
Aicuris Presents Positive Phase 3 Data for Pritelivir in Immunocompromised Patients with Refractory Herpes Simplex Virus at TANDEM
05/02/2026
Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with standard-of-care therapies (investigator’s choice), resulting in an adjusted treatment [...]
Vistin Pharma ASA (VISTN): Invitation to Q4 2025 conference call
05/02/2026
Oslo, Norway, 5 February 2026 Vistin Pharma ASA will release its fourth quarter and preliminary 2025 results on Thursday 12th of February 2025. Vistin Pharma will host a conference call for all shareholders and [...]
Biocomposites gains MDR certification for STIMULAN® Rapid Cure and STIMULAN® Kit
05/02/2026
STIMULAN ® certified to be mixed with a combination of Gram-positive and Gram-negative antibiotics STIMULAN ® certified to resolve infection and reduce the need for secondary surgery STIMULAN ® is the only calcium [...]
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
05/02/2026
The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio® in healthy adult participants, met all its primary endpoints REYKJAVIK, ICELAND (February 5, 2026) – [...]
Zelluna ASA: Invitation to Fourth Quarter 2025 Results Webcast Presentation
05/02/2026
Oslo, Norway, 5 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, invites to a webcast presentation [...]
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
05/02/2026
The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio ® in healthy adult participants, met all its primary endpoints REYKJAVIK, Iceland, Feb. 05, 2026 ( [...]
Fagron obtains regulatory clearance for the acquisition of Vepakum in Brazil and completes the acquisition of Magilab in Hungary
05/02/2026
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 5 February 2026 Fagron obtains regulatory clearance for the acquisition of Vepakum in Brazil and completes the acquisition of [...]
GN Annual Report 2025: Solid execution leading to market share gains, DKK 1.1 billion free cash flow, and a strong foundation for profitable growth in the years ahead
05/02/2026
2025 highlights GN delivered revenue of DKK 16.8 billion with organic revenue growth of -1% (excluding wind-down), The Hearing division took market share – for the 4 th consecutive year – leading to 5% organic revenue [...]
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer
05/02/2026
BMC128 was developed by Biomica, Evogene’s subsidiary, and is currently completing Phase 1 clinical study, showing promising early clinical results REHOVOT, Israel and SHANGHAI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Evogene [...]

Pages